The RNOH will remain the UK’s leading specialist orthopaedic hospital, further enhancing its international profile for outstanding patient care, research and education

Professor Adrienne M Flanagan

Professor Adrienne M Flanagan

Prof Flanagan, joint medical director, honory consultant histopathologist
Professor Adrienne M Flanagan MB, BCh, BAO, LRCPI, LRCSI, FRCPath, PhD, FMedSci
Position:
Consultant Histopathologist, Clinical lead
Email:
adrienne.flanagan@rnoh.nhs.uk
Telephone:
+44 (0)20 8909 5354
Fax:
+44 (0)20 8954 5908
Specialties:
Histopathology
Specialist clinical interests:
Cell and molecular pathology of bone and soft tissue tumours and non-neoplastic musculoskeletal disorders.
Research interests:

Cell biology and genetics of sarcoma.
Discovering new diagnostic signatures for sarcoma.
Identifying markers to predict clinical outcome for sarcoma.

Professional profile:

Consultant Pathologist at the Royal National Orthopaedic Hospital
Honorary Consultant, Nuffield Orthopaedic Centre, Oxford
Professor of Musculoskeletal Pathology, UCL
Cancer Lead for 100,000 Genome Project: North Thames Genome Medicine Centre
Lead for Genomics England Clinical Interpretation Partnership (GeCIP) - Sarcoma
Lead scientist of the cell and genetics of sarcoma team at UCL Cancer Institute
Corporate License Holder for the Human Tissue Authority license, UCL
Biomedical Research Centre (UCLH/UCL), Cancer Programme Deputy Director
Editor for Recent Advances in Histopathology
Consultant to Agios Pharmaceutical
Supervised 16 PhD students since 1996 (9 primary supervisor), including two current students
Generated £3M for research since 2012
Published more than 130 peer-reviewed manuscripts

Education and training:

FRCPath Part 2 Course (bi-annual) East of England Deanery. Bone and soft tissue disease.
London Deanery Thames Region: ST1 bone and soft tissue pathology. Annual.
London Deanery: SpR bone and soft tissue pathology (every two years).
UCL Cancer Institute MSc: Biomarkers in cancer. Annual.
University representative of the London Deanery specialist training committee for histopathologists.

Memberships:
UCL Cancer Institute, executive committee member
Clinical lead, International Cancer Genome Consortium Bone Project
Pathological Society of Great Britain and Ireland, committee member and meeting secretary
London Deanery, School of Pathology, Training programme Management Committee – molecular pathology sub-specialty
International Skeletal Society, Member-At-Large of the executive committee
External Scientific Advisory Committee, Memorial Sloan-Kettering NIH funded SPORE in Soft Tissue Sarcoma
International Skeletal Society, Member-At-Large of the executive committee
Jean Shanks Foundation, Trustee
Chordoma Foundation, Scientific Advisory Board
SCAT (Skeletal Cancer Action Trust), Trustee/Board member
Royal College of Pathologists, National Quality Assurance Advisory Panel – Pathological Society representative
Editorial Board, Journal of Pathology
Editorial Board, The Open Pathology Journal www.benthamscience.org/open/topatj
Editorial Board, Skeletal Radiology
Editorial Board, Clinical Sarcoma Research
Scientific Advisory Board Member, Sarah Cannon Research UK
Research Advisory Committee, Sarcoma UK
Royal College of Pathologists representative for NICE guidelines for sarcomas
Member of the Scientific Advisory Committee, Celltech
Previous responsibilities:
Designated Individual of Human Tissue Authority licence (Research), UCL (2009-2012)
Joint Medical Director, RNOH (2009 – 2012)
Cancer Research UK Stratified Medicine, scientific advisory board member (2010-2011)
Chair of the Medical Staff Committee RNOH (2007-2009)
Co-Chair of the Medical Staff Committee RNOH (2005-2007)
Pathological Society of Great Britain and Ireland (2007-2009), Committee Member
Professor Flanagan is a guest Faculty Member at The 5th Annual Sacro Pelvic Tumor Study Group Conference held by the Massachusetts General Hospital (Boston, MA), the Mayo Clinic (Rochester, MN) and the Memorial Sloan-Kettering Cancer Center (New York, NY). The conference was founded in 2008 as a collaboration with Massachusetts General Hospital (Boston, MA ), the Mayo Clinic (Rochester, MN) and the Memorial Sloan-Kettering Cancer Center (New York, NY).
Consultant to Casdin Capital, LLC
Prizes Committee Member: International Skeletal Society
Committee member of the National Quality Assurance Advisory Panel – Pathological Society Representative
International Skeletal Society, Member-At-Large of the Executive Committee
Educational Supervisor (Histopathology), RNOH
Presentations and conferences:

Previous invited lectures, and teaching courses

  1. December 2016 -12th Arab-British school of pathology workshop. Arab Division of the International Academy of Pathology. Morocco.
  2. July 2016 - Chordoma Research Workshop. Chordoma Foundation. Boston, USA.
  3. June 2016 - Australasian Division of the International Academy of Pathology, Brisbane. Plenary lecture.
  4. May 2016 - Multiple Herditary Exostosis Research Foundation Conference, Palm Beach, Florida. Declined.
  5. December 2015 - ESMO Asia 2015 Scientific Committee, Singapore. Declined.
  6. November 2015 - Brazilian Congress of Pathology 2015. Sao Paulo, Brazil.
  7. August 2015 - British Division of the International Academy of Pathology: Sri Lankan School of Pathology. Soft tissue and bone tumour teaching.
  8. July 2015 - Chordoma research meeting (closed meeting), New York USA.
  9. 2015 - Human Oncology and Pathogenesis Program (HOPP) Memorial Sloan-Kettering Cancer Center. Declined
  10. April 2015 - Lecture on cancer genetics Radboudumc, Geert Grooteplein, Nijmegen, The Netherlands.. Deferred.
  11. February 2015 -  “Rare Cancers” symposium, Tokoyo. National Cancer Center Hospital, Japan.  Declined.
  12. November 2014  Inaugural Irish Sarcoma Group Meeting: evolution of molecular pathology.  Irish Sarcoma Group.
  13. September 2014 Trainees Symposium London 2014 Joint Path Soc ESP meeting. Pathological Society of Great Britain and Ireland.
  14. September 2014 Crick/Sanger Retreat, Oxford.
  15. September 2014 MoM Hip Replacements London Meeting.  Royal & National Orthopeadic Hosptial, London.
  16. June 2014 Second European Chordoma Conference, Frankfurt.  European Chordoma Foundataion. 
  17. May 2014  ALVAL: Histological description and interpretation.  Ghent University Hospital, Belgium.
  18. 2014 March 4th German Sarcoma Conference, Berlin - Basic pathology and functional genomics in chordoma
  19. 2014 March The IX Brazilian Oncologic Orthopedics Association Congress and The VIII Latin American Musculoskeletal Tumor Society Congress.  The genetics of osteoclast-rich tumours of bone
  20. February 2014 Applying Chromatin Biology to Understand Diffuse Intrinsic Pontine Glioma.  National Cancer Institute, UK.
  21. 2014 Jan Memorial Sloan Kettering, Mayo Clinic and Harvard annual sacral study meeting: management of chordoma
  22. 2013 Dec IAP Hong Kong Division Histopathology short course
  23. 2013 Dec Ho Chi Minh City Oncology Hospital, Ho Chi Minh City (Saigon), Vietnam
  24. 2013 Oct 3rd International Sarcoma Biology Meeting, New York. Genetics of chondrosarcoma
  25. 2013 Jan Path Soc Winter Meeting University Medical Centre Utrecht
  26. 2013 June Path Soc / BDIAP. Edinburgh. What genomic profiling of bone tumours brings to patients.
  27. 2013 Jan 28th- 31st  Arab Health Dubai
  28. June 2012: First European Chordoma Foundation meeting, organised by patients for patients. The pathology of chordoma.
  29. 2012 Oct: International Association of Pathologists, Annual meeting. S. Africa. Molecular genetics of chordoma.
  30. 2012 Oct: International Association of Pathologists, Annual meeting. S. Africa. Hardcastle Syndrome.
  31. 2012 Oct: International Association of Pathologists, Annual meeting. S. Africa. Spindle cell and non-epithelial lesions of the genitourinary tract.
  32. 2012 March: AGIOS Pharmaceuticals, Inc. Boston, USA. IDH1 mutations in cartilaginous tumours.
  33. 2012 March: Durham Academy / high school, N. Carolina, USA: The history of pathology, and developing new treatments for chordoma. I spoke to the class in which a child in this school died of chordoma. I had met the child and family in 2007. I also used took the opportunity to meet with scientists in Duke University, & GSK pharmaceuticals.
  34. 2012 March: Sarcoma UK Society, Annual meeting: The International Cancer Genome Project.
  35. 2012 March: Sarcoma UK Society, Annual meeting: Introducing new therapies for treatment of sarcoma.
  36. 2011 Sept: European Society of Pathology, Helsinki: Chordoma: molecular insights & potential target identification.
  37. 2011 Apr: Jordanian Society of Pathology, Annual meeting. Benefits of molecular pathology in bone & soft tissue tumours
  38. 2011 Apr: Association for Clinical Cytogenetics, Annual meeting. Durham, Scotland. The value of molecular pathology in providing a clinical service.
  39. 2011 Mar: Chordoma Foundation meeting. The role of brachyury in chordoma, for researchers.
  40. 2011 Mar: Lecture to patients and families members, with chordoma. Diagnosing and treating chordomas.
  41. 2010 Nov: Childhood Bone Sarcoma Genomics Consortium representing the Wellcome Trust Sanger Institute. Paris meeting.
  42. 2010 Nov: Problematic low grade lesions in bone and soft tissue. RCPath course.
  43. 2010 Jul: 43rd Annual Musculoskeletal Tumour Meeting, Japanese Orthopaedic Association. Molecular genetics of chordoma.
  44. 2010 Jul: 43rd Annual Musculoskeletal Tumour Meeting, Japanese Orthopaedic Association. The pathology of osteoclast-rich tumours.
  45. 2009 Jun: International Cancer Genome Consortium, First meeting at Wellcome Trust Sanger Institute. ‘Bone tumours project – Sequencing 500 bone tumours’.
  46. 2010 May: Problematic high grade lesions in bone and soft tissue. RCPath course.
  47. 2010 Feb: World Association of Societies of Pathology and Laboratory Medicine (WASPaLM). Chandigarh India. Lectures on bone tumour pathology to post graduates/consultants
  48. 2009 Jun: Bone Cancer Research Trust. Lecture to patients/families with bone tumours. How molecular pathology will provide new therapeutic targets.
  49. 2008 Nov: World Association of Societies of Pathology and Laboratory Medicine (WASPaLM), Anatomical Pathology Update, Penang, Malaysia. Bone and Soft tissue Lectures and Seminars.
  50. 2008 Oct: International Skeletal Society, Delhi India. Osteoarthritis – latest facts and fiction.
  51. 2008 Oct: International Academy of Pathologists. Greece. Mimics of malignancy in bone and soft tissue lesions.
  52. 2008 Jun: 14th International Congress of Oral Pathology and Medicine. San Francisco. Molecular genetic events in fibro-osseous and osteoclast-rich lesions of the jaw. Lecture and Seminar.
Publications:
  1. Coulter IC, Khan SA, Flanagan AM, Marks SM. Chiari I. (2014) Malformation associated with Gorham's disease of the skull base. Clin Neurol Neurosurg. Jan;116:83-6.
  2. Feber A, Guilhamon P, Lechner M, Fenton T, Wilson GA, Thirlwell C, Morris TJ,Flanagan AM, Teschendorff AE, Kelly JD, Beck S. (2014) Using high-density DNA methylation arrays to profile copy number alterations. Genome Biol. Feb 3;15(2):R30.
  3. Cooke SL, Shlien A, Marshall J, Pipinikas CP, Martincorena I, Tubio JM, Li Y, Menzies A, Mudie L, Ramakrishna M, Yates L, Davies H, Bolli N, Bignell GR, Tarpey PS, Behjati S, Nik-Zainal S, Papaemmanuil E, Teixeira VH, Raine K, O'Meara S, Dodoran MS, Teague JW, Butler AP, Iacobuzio-Donahue C, Santarius T, Grundy RG, Malkin D, Greaves M, Munshi N, Flanagan AM, Bowtell D, Martin S, Larsimont D, Reis-Filho JS, Boussioutas A, Taylor JA, Hayes ND, Janes SM, Futreal PA, Stratton MR, McDermott U, Campbell PJ. (2014) Processed pseudogenes acquired somatically during cancer development. ICGC Breast Cancer Group. Nat Commun. Apr 9;5:3644.
  4. Behjati S, Tarpey PS, Sheldon H, Martincorena I, Van Loo P, Gundem G, Wedge DC, Ramakrishna M, Cooke SL, Pillay N, Vollan HK, Papaemmanuil E, Koss H, Bunney TD, Hardy C, Joseph OR, Martin S, Mudie L, Butler A, Teague JW, Patil M, Steers G, Cao Y, Gumbs C, Ingram D, Lazar AJ, Little L, Mahadeshwar H, Protopopov A, Al Sannaa GA, Seth S, Song X, Tang J, Zhang J, Ravi V, Torres KE, Khatri B, Halai D, Roxanis I, Baumhoer D, Tirabosco R, Amary MF, Boshoff C, McDermott U, Katan M, Stratton MR, Futreal PA, Flanagan AM, Harris A, Campbell PJ. (2014). Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nat Genet. Apr;46(4):376-9.
  5. Aitken SJ, Presneau N, Tirabosco R, Amary MF, O'Donnell P, Flanagan AM. (2014) An NRAS mutation in a case of Erdheim Chester disease. Histopathology. Apr 23;65(6) 1365-2559.
  6. Amary M, Ye H, Berisha F, Khatri B, Forbes G, Lehovsky K, Frezza AM, Behjati S, Tarpey P, Pillay N, Campbel PJ, Tirabosco T, Presneau N, Strauss SJ, Flanagan AM. (2014) Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with a poor response to neo-adjuvant chemotherapy. Cancer Med. Aug;3(4):980-7.
  7. Wang Z, Zhu B, Zhang M, Parikh H, Jia J, Chung CC, Sampson JN, Hoskins JW, Hutchinson A, Burdette L, Ibrahim A, Hautman C, Raj PS, Abnet CC, Adjei AA, Ahlbom A, Albanes D, Allen NE, Ambrosone CB, Aldrich M, Amiano P, Amos C, Andersson U, Andriole G Jr, Andrulis IL, Arici C, Arslan AA, Austin MA, Baris D, Barkauskas DA, Bassig BA, Beane Freeman LE, Berg CD, Berndt SI, Bertazzi PA, Biritwum RB, Black A, Blot W, Boeing H, Boffetta P, Bolton K, Boutron-Ruault MC, Bracci PM, Brennan P, Brinton LA, Brotzman M, Bueno-de-Mesquita HB, Buring JE, Butler MA, Cai Q, Cancel-Tassin G, Canzian F, Cao G, Caporaso NE, Carrato A, Carreon T, Carta A, Chang GC, Chang IS, Chang-Claude J, Che X, Chen CJ, Chen CY, Chen CH, Chen C, Chen KY, Chen YM, Chokkalingam AP, Chu LW, Clavel-Chapelon F, Colditz GA, Colt JS, Conti D, Cook MB, Cortessis VK, Crawford ED, Cussenot O, Davis FG, De Vivo I, Deng X, Ding T, Dinney CP, Di Stefano AL, Diver WR, Duell EJ, Elena JW, Fan JH, Feigelson HS, Feychting M, Figueroa JD, Flanagan AM, Fraumeni JF Jr, Freedman ND, Fridley BL, Fuchs CS, Gago-Dominguez M, Gallinger S, Gao YT, Gapstur SM, Garcia-Closas M, Garcia-Closas R, Gastier-Foster JM, Gaziano JM, Gerhard DS, Giffen CA, Giles GG, Gillanders EM, Giovannucci EL, Goggins M, Gokgoz N, Goldstein AM, Gonzalez C, Gorlick R, Greene MH, Gross M, Grossman HB, Grubb R 3rd, Gu J, Guan P, Haiman CA, Hallmans G, Hankinson SE, Harris CC, Hartge P, Hattinger C, Hayes RB, He Q, Helman L, Henderson BE, Henriksson R, Hoffman-Bolton J, Hohensee C, Holly EA, Hong YC, Hoover RN, Hosgood HD 3rd, Hsiao CF, Hsing AW, Hsiung CA, Hu N, Hu W, Hu Z, Huang MS, Hunter DJ, Inskip PD, Ito H, Jacobs EJ, Jacobs KB, Jenab M, Ji BT, Johansen C, Johansson M, Johnson A, Kaaks R, Kamat AM, Kamineni A, Karagas M, Khanna C, Khaw KT, Kim C, Kim IS, Kim YH, Kim YC, Kim YT, Kang CH, Jung YJ, Kitahara CM, Klein AP, Klein R, Kogevinas M, Koh WP, Kohno T, Kolonel LN, Kooperberg C, Kratz CP, Krogh V, Kunitoh H, Kurtz RC, Kurucu N, Lan Q, Lathrop M, Lau CC, Lecanda F, Lee KM, Lee MP, Le Marchand L, Lerner SP, Li D, Liao LM, Lim WY, Lin D, Lin J, Lindstrom S, Linet MS, Lissowska J, Liu J, Ljungberg B, Lloreta J, Lu D, Ma J, Malats N, Mannisto S, Marina N, Mastrangelo G, Matsuo K, McGlynn KA, McKean-Cowdin R, McNeill LH, McWilliams RR, Melin BS, Meltzer PS, Mensah JE, Miao X, Michaud DS, Mondul AM, Moore LE, Muir K, Niwa S, Olson SH, Orr N, Panico S, Park JY, Patel AV, Patino-Garcia A, Pavanello S, Peeters PH, Peplonska B, Peters U, Petersen GM, Picci P, Pike MC, Porru S, Prescott J, Pu X, Purdue MP, Qiao YL, Rajaraman P, Riboli E, Risch HA, Rodabough RJ, Rothman N, Ruder AM, Ryu JS, Sanson M, Schned A, Schumacher FR, Schwartz AG, Schwartz KL, Schwenn M, Scotlandi K, Seow A, Serra C, Serra M, Sesso HD, Severi G, Shen H, Shen M, Shete S, Shiraishi K, Shu XO, Siddiq A, Sierrasesumaga L, Sierri S, Loon Sihoe AD, Silverman DT, Simon M, Southey MC, Spector L, Spitz M, Stampfer M, Stattin P, Stern MC, Stevens VL, Stolzenberg-Solomon RZ, Stram DO, Strom SS, Su WC, Sund M, Sung SW, Swerdlow A, Tan W, Tanaka H, Tang W, Tang ZZ, Tardon A, Tay E, Taylor PR, Tettey Y, Thomas DM, Tirabosco R, Tjonneland A, Tobias GS, Toro JR, Travis RC, Trichopoulos D, Troisi R, Truelove A, Tsai YH, Tucker MA, Tumino R, Van Den Berg D, Van Den Eeden SK, Vermeulen R, Vineis P, Visvanathan K, Vogel U, Wang C, Wang C, Wang J, Wang SS, Weiderpass E, Weinstein SJ, Wentzensen N, Wheeler W, White E, Wiencke JK, Wolk A, Wolpin BM, Wong MP, Wrensch M, Wu C, Wu T, Wu X, Wu YL, Wunder JS, Xiang YB, Xu J, Yang HP, Yang PC, Yatabe Y, Ye Y, Yeboah ED, Yin Z, Ying C, Yu CJ, Yu K, Yuan JM, Zanetti KA, Zeleniuch-Jacquotte A, Zheng W, Zhou B, Mirabello L, Savage SA, Kraft P, Chanock SJ, Yeager M, Landi MT, Shi J, Chatterjee N, Amundadottir LT. (2014) Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet. Dec 15;23(24):6616-33.
  8. Tubio JM, Li Y, Ju YS, Martincorena I, Cooke SL, Tojo M, Gundem G, Pipinikas CP, Zamora J, Raine K, Menzies A, Roman-Garcia P, Fullam A, Gerstung M, Shlien A, Tarpey PS, Papaemmanuil E, Knappskog S, Van Loo P, Ramakrishna M, Davies HR, Marshall J, Wedge DC, Teague JW, Butler AP, Nik-Zainal S, Alexandrov L, Behjati S, Yates LR, Bolli N, Mudie L, Hardy C, Martin S, McLaren S, O'Meara S, Anderson E, Maddison M, Gamble S; ICGC Breast Cancer Group; ICGC Bone Cancer Group; ICGC Prostate Cancer Group, Foster C, Warren AY, Whitaker H, Brewer D, Eeles R, Cooper C, Neal D, Lynch AG, Visakorpi T, Isaacs WB, van't Veer L, Caldas C, Desmedt C, Sotiriou C, Aparicio S, Foekens JA, Eyfjörd JE, Lakhani SR, Thomas G, Myklebost O, Span PN, Børresen-Dale AL, Richardson AL, Van de Vijver M, Vincent-Salomon A, Van den Eynden GG, Flanagan AM, Futreal PA, Janes SM, Bova GS, Stratton MR, McDermott U, Campbell PJ. (2014) Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. Science. Aug 1;345(6196):1251343.
  9. Ju YS, Alexandrov LB, Gerstung M, Martincorena I, Nik-Zainal S, Ramakrishna M, Davies HR, Papaemmanuil E, Gundem G, Shlien A, Bolli N, Behjati S, Tarpey PS, Nangalia J, Massie CE, Butler AP, Teague JW, Vassiliou GS, Green AR, Du MQ, Unnikrishnan A, Pimanda JE, Teh BT, Munshi N, Greaves M, Vyas P, El-Naggar AK, Santarius T, Collins VP, Grundy R, Taylor JA, Hayes DN, Malkin D; ICGC Breast Cancer Group; ICGC Chronic Myeloid Disorders Group; ICGC Prostate Cancer Group, Foster CS, Warren AY, Whitaker HC, Brewer D, Eeles R, Cooper C, Neal D, Visakorpi T, Isaacs WB, Bova GS, Flanagan AM, Futreal PA, Lynch AG, Chinnery PF, McDermott U, Stratton MR, Campbell PJ. (2014) Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. Elife. Oct 1;3. doi: 10.7554/eLife.02935.
  10. Ban J, Aryee DN, Fourtouna A, van der Ent W, Kauer M, Niedan S, Machado I, Rodriguez-Galindo C, Tirado OM, Schwentner R, Picci P, Flanagan AM, Berg V, Strauss SJ, Scotlandi K, Lawlor ER, Snaar-Jagalska E, Llombart-Bosch A, Kovar H. (2014). Suppression of Deacetylase SIRT1 Mediates Tumor-Suppressive NOTCH Response and Offers a Novel Treatment Option in Metastatic Ewing Sarcoma. Cancer Res. Nov 15;74(22):6578-88.
  11. Guilhamon P, Butcher LM, Presneau N, Wilson GA, Feber A, Paul DS, Schütte M, Haybaeck J, Keilholz U, Hoffman J, Ross MT, Flanagan AM, Beck S. (2014). Assessment of patient-derived tumour xenografts (PDXs) as a discovery tool for cancer epigenomics. Genome Med. 2014 Dec 12;6(12):116.
  12. Flanagan AM, Speight PM. (2014). Giant cell lesions of the craniofacial bones. Head Neck Pathol. 2014 Dec;8(4):445-53.
  13. Amary MF, Ye H, Forbes G, Damato S, Maggiani F, Pollock R, Tirabosco R, Flanagan AM. (2015). Isocitrate dehydrogenase 1 mutations (IDH1) and p16/CDKN2A copy number change in conventional chondrosarcomas. Virchows Arch. 2015 Feb;466(2):217-22.
  14. Whelan JS, Bielack SS, Marina N, Smeland S, Jovic G, Hook JM, Krailo M, Anninga J, Butterfass-Bahloul T, Böhling T, Calaminus G, Capra M, Deffenbaugh C, Dhooge C, Eriksson M, Flanagan AM, Gelderblom H, Goorin A, Gorlick R, Gosheger G, Grimer RJ, Hall KS, Helmke K, Hogendoorn PC, Jundt G, Kager L, Kuehne T, Lau CC, Letson GD, Meyer J, Meyers PA, Morris C, Mottl H, Nadel H, Nagarajan R, Randall RL, Schomberg P, Schwarz R, Teot LA, Sydes MR, Bernstein M; EURAMOS collaborators. (2015). EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Ann Oncol. 2015 Feb;26(2):407-414.
  15. Aitken SJ, Presneau N, Kalimuthu S, Dileo P, Berisha F, Tirabosco R, Amary MF, Flanagan AM. (2015) Next-generation sequencing is highly sensitive for the detection of beta-catenin mutations in desmoid-type fibromatoses. Virchows Arch. Apr; 467(2): 203-210.
  16. Horlings HM, Flanagan AM, Huntsman DG. (2015) Categorization of cancer through genomic-complexity could guide research and management strategies. J Pathol. Aug. 236(4):397-402.
  17. Presneau N, Baumhoer D, Behjati S, Pillay N, Tarpey P, Campbell PJ, Jundt G, Hamoudi R, Wedge DC, Van Loo P, Hassan AB, Khatri B, Ye H, Tirabosco R, Amary MF, Flanagan AM. (2015) Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics. J Pathol Clin Res. J Pathol Clin Res. April:1(2):113–123.
  18. Kalimuthu S, Tilley C, Forbes G, Ye H, Lehovsky K, Pillay N, Seddon B, O’Donnell P, Pollock R, Tirabosco R, Amary F, Flanagan AM. (2015) Clinical outcoms in patients with peripherally-sited atypical lipomatous tumours and dedifferentiated liposarcoma. J Pathol: Clin Res, 1: 106–112
  19. Seddon B, Scurr M, Jones RL, Wood Z, Propert-Lewis C, Fisher C, Flanagan AM, Sunkersing J, A'Hern R, Whelan J, Judson I. (2015) A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma. Clin Sarcoma Res. May:16;5:13.
  20. Aitken SJ, Presneau N, Khatri B, Flanagan AM, Clarke B, McCluggage WG. (2015) Mutations in IDH1 and IDH2 are not present in sporadic ovarian sex cord-stromal tumours. Histopathology. May;66(6):897-8.
  21. Ju YS, Tubio JM, Mifsud W, Fu B, Davies HR, Ramakrishna M, Li Y, Yates L, Gundem G, Tarpey PS, Behjati S, Papaemmanuil E, Martin S, Fullam A, Gerstung M; ICGC Prostate Cancer Working Group; ICGC Bone Cancer Working Group; ICGC Breast Cancer Working Group, Nangalia J, Green AR, Caldas C, Borg Å, Tutt A, Lee MT, van't Veer LJ, Tan BK, Aparicio S, Span PN, Martens JW, Knappskog S, Vincent-Salomon A, Børresen-Dale AL, Eyfjörd JE, Flanagan AM, Foster C, Neal DE, Cooper C, Eeles R, Lakhani SR, Desmedt C, Thomas G, Richardson AL, Purdie CA, Thompson AM, McDermott U, Yang F, Nik-Zainal S, Campbell PJ, Stratton MR. (2015) Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. Genome Res.Jun;25(6):814-24
  22. Mirabello L, Koster R, Moriarity BS, Spector LG, Meltzer PS, Gary J, Machiela MJ, Pankratz N, Panagiotou OA, Largaespada D, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, de Toledo SR, Petrilli AS, Patiño-Garcia A, Sierrasesúmaga L, Lecanda F, Andrulis IL, Wunder JS, Gokgoz N, Serra M, Hattinger C, Picci P, Scotlandi K, Flanagan AM, Tirabosco R, Amary MF, Halai D, Ballinger ML, Thomas DM, Davis S, Barkauskas DA, Marina N, Helman L, Otto GM, Becklin KL, Wolf NK, Weg MT, Tucker M, Wacholder S, Fraumeni JF Jr, Caporaso NE, Boland JF, Hicks BD, Vogt A, Burdett L, Yeager M, Hoover RN, Chanock SJ, Savage SA. (2015) A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma. Cancer Discov. Sep;5(9):920-31
  23. Saunus JM, Quinn MC, Patch AM, Pearson JV, Bailey PJ, Nones K, McCart Reed AE, Miller D, Wilson PJ, Al-Ejeh F, Mariasegaram M, Lau Q, Withers T, Jeffree RL, Reid LE, Da Silva L, Matsika A, Niland CM, Cummings MC, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Wani S, Anderson MJ, Fink JL, Holmes O, Kazakoff S, Leonard C, Newell F, Taylor D, Waddell N, Wood S, Xu Q, Kassahn KS, Narayanan V, Taib NA, Teo SH, Chow YP, kConFab, Jat PS, Brandner S, Flanagan AM, Khanna KK, Chenevix-Trench G, Grimmond SM, Simpson PT, Waddell N, Lakhani SR. (2015) Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance. J Pathol.Nov;237(3):363-78
  24. Salinas-Souza C, De Andrea C, Bihl M, Kovac M, Pillay N, Forshew T, Gutteridge A, Ye H, Amary MF, Tirabosco R, Toledo SR, Baumhoer D, Flanagan AM. (2015) GNAS mutations are not detected in parosteal and low-grade central osteosarcomas. Mod Pathol. Oct;28(10):1336-42.
  25. Lorenz S, Barøy T, Sun J, Nome T, Vodák D, Bryne JC, Håkelien AM, Fernandez-Cuesta L, Möhlendick B, Rieder H, Szuhai K, Zaikova O, Ahlquist TC, Thomassen GO, Skotheim RI, Lothe RA, Tarpey PS, Campbell P, Flanagan AM, Myklebost O, Meza-Zepeda LA. (2015) Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations. Oncotarget. 2015 Dec 11.
  26. Sampson JN, Wheeler WA, Yeager M, Panagiotou O, Wang Z, Berndt SI, Lan Q, Abnet CC, Amundadottir LT, Figueroa JD, Landi MT, Mirabello L, Savage SA, Taylor PR, De Vivo I, McGlynn KA, Purdue MP, Rajaraman P, Adami HO, Ahlbom A, Albanes D, Amary MF, An SJ, Andersson U, Andriole G Jr, Andrulis IL, Angelucci E, Ansell SM, Arici C, Armstrong BK, Arslan AA, Austin MA, Baris D, Barkauskas DA, Bassig BA, Becker N, Benavente Y, Benhamou S, Berg C, Van Den Berg D, Bernstein L, Bertrand KA, Birmann BM, Black A, Boeing H, Boffetta P, Boutron-Ruault MC, Bracci PM, Brinton L, Brooks-Wilson AR, Bueno-de-Mesquita HB, Burdett L, Buring J, Butler MA, Cai Q, Cancel-Tassin G, Canzian F, Carrato A, Carreon T, Carta A, Chan JK, Chang ET, Chang GC, Chang IS, Chang J, Chang-Claude J, Chen CJ, Chen CY, Chen C, Chen CH, Chen C, Chen H, Chen K, Chen KY, Chen KC, Chen Y, Chen YH, Chen YS, Chen YM, Chien LH, Chirlaque MD, Choi JE, Choi YY, Chow WH, Chung CC, Clavel J, Clavel-Chapelon F, Cocco P, Colt JS, Comperat E, Conde L, Connors JM, Conti D, Cortessis VK, Cotterchio M, Cozen W, Crouch S, Crous-Bou M, Cussenot O, Davis FG, Ding T, Diver WR, Dorronsoro M, Dossus L, Duell EJ, Ennas MG, Erickson RL, Feychting M, Flanagan AM, Foretova L, Fraumeni JF Jr, Freedman ND, Beane Freeman LE, Fuchs C, Gago-Dominguez M, Gallinger S, Gao YT, Gapstur SM, Garcia-Closas M, García-Closas R, Gascoyne RD, Gastier-Foster J, Gaudet MM, Gaziano JM, Giffen C, Giles GG, Giovannucci E, Glimelius B, Goggins M, Gokgoz N, Goldstein AM, Gorlick R, Gross M, Grubb R 3rd, Gu J, Guan P, Gunter M, Guo H, Habermann TM, Haiman CA, Halai D, Hallmans G, Hassan M, Hattinger C, He Q, He X, Helzlsouer K, Henderson B, Henriksson R, Hjalgrim H, Hoffman-Bolton J, Hohensee C, Holford TR, Holly EA, Hong YC, Hoover RN, Horn-Ross PL, Hosain GM, Hosgood HD 3rd, Hsiao CF, Hu N, Hu W, Hu Z, Huang MS, Huerta JM, Hung JY, Hutchinson A, Inskip PD, Jackson RD, Jacobs EJ, Jenab M, Jeon HS, Ji BT, Jin G, Jin L, Johansen C, Johnson A, Jung YJ, Kaaks R, Kamineni A, Kane E, Kang CH, Karagas MR, Kelly RS, Khaw KT, Kim C, Kim HN, Kim JH, Kim JS, Kim YH, Kim YT, Kim YC, Kitahara CM, Klein AP, Klein RJ, Kogevinas M, Kohno T, Kolonel LN, Kooperberg C, Kricker A, Krogh V, Kunitoh H, Kurtz RC, Kweon SS, LaCroix A, Lawrence C, Lecanda F, Lee VH, Li D, Li H, Li J, Li YJ, Li Y, Liao LM, Liebow M, Lightfoot T, Lim WY, Lin CC, Lin D, Lindstrom S, Linet MS, Link BK, Liu C, Liu J, Liu L, Ljungberg B, Lloreta J, Di Lollo S, Lu D, Lund E, Malats N, Mannisto S, Le Marchand L, Marina N, Masala G, Mastrangelo G, Matsuo K, Maynadie M, McKay J, McKean-Cowdin R, Melbye M, Melin BS, Michaud DS, Mitsudomi T, Monnereau A, Montalvan R, Moore LE, Mortensen LM, Nieters A, North KE, Novak AJ, Oberg AL, Offit K, Oh IJ, Olson SH, Palli D, Pao W, Park IK, Park JY, Park KH, Patiño-Garcia A, Pavanello S, Peeters PH, Perng RP, Peters U, Petersen GM, Picci P, Pike MC, Porru S, Prescott J, Prokunina-Olsson L, Qian B, Qiao YL, Rais M, Riboli E, Riby J, Risch HA, Rizzato C, Rodabough R, Roman E, Roupret M, Ruder AM, Sanjose Sd, Scelo G, Schned A, Schumacher F, Schwartz K, Schwenn M, Scotlandi K, Seow A, Serra C, Serra M, Sesso HD, Setiawan VW, Severi G, Severson RK, Shanafelt TD, Shen H, Shen W, Shin MH, Shiraishi K, Shu XO, Siddiq A, Sierrasesúmaga L, Sihoe AD, Skibola CF, Smith A, Smith MT, Southey MC, Spinelli JJ, Staines A, Stampfer M, Stern MC, Stevens VL, Stolzenberg-Solomon RS, Su J, Su WC, Sund M, Sung JS, Sung SW, Tan W, Tang W, Tardón A, Thomas D, Thompson CA, Tinker LF, Tirabosco R, Tjønneland A, Travis RC, Trichopoulos D, Tsai FY, Tsai YH, Tucker M, Turner J, Vajdic CM, Vermeulen RC, Villano DJ, Vineis P, Virtamo J, Visvanathan K, Wactawski-Wende J, Wang C, Wang CL, Wang JC, Wang J, Wei F, Weiderpass E, Weiner GJ, Weinstein S, Wentzensen N, White E, Witzig TE, Wolpin BM, Wong MP, Wu C, Wu G, Wu J, Wu T, Wu W, Wu X, Wu YL, Wunder JS, Xiang YB, Xu J, Xu P, Yang PC, Yang TY, Ye Y, Yin Z, Yokota J, Yoon HI, Yu CJ, Yu H, Yu K, Yuan JM, Zelenetz A, Zeleniuch-Jacquotte A, Zhang XC, Zhang Y, Zhao X, Zhao Z, Zheng H, Zheng T, Zheng W, Zhou B, Zhu M, Zucca M, Boca SM, Cerhan JR, Ferri GM, Hartge P, Hsiung CA, Magnani C, Miligi L, Morton LM, Smedby KE, Teras LR, Vijai J, Wang SS, Brennan P, Caporaso NE, Hunter DJ, Kraft P, Rothman N, Silverman DT, Slager SL, Chanock SJ, Chatterjee N. (2015) Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. J Natl Cancer Inst. Oct 12;107(12).
  27. Gray MJ, Kannu P, Sharma S, Neyt C, Zhang D, Paria N, Daniel PB, Whetstone H, Sprenger HG, Hammerschmidt P, Weng A, Dupuis L, Jobling R, Mendoza-Londono R, Dray M, Su P, Wilson MJ, Kapur RP, McCarthy EF, Alman BA, Howard A, Somers GR, Marshall CR, Manners S, Flanagan AM, Rathjen KE, Karol LA, Crawford H, Markie DM, Rios JJ, Wise CA, Robertson SP. (2015) Mutations Preventing Regulated Exon Skipping in MET Cause Osteofibrous Dysplasia. Am J Hum Genet. Dec 3;97(6):837-47.
  28. Amary MF, Berisha F, Mozela R, Gibbons R, Guttridge A, O'Donnell P, Baumhoer D, Tirabosco R, Flanagan AM. (2016) The H3F3 K36M mutant antibody is a sensitive and specific marker for the diagnosis of chondroblastoma. Histopathology. Feb 4.
  29. Scheipl S, Barnard M, Cottone L, Jorgensen M, Drewry D, Zuercher WJ, Turlais F, Ye H, Leite AP, Smith JA, Leithner A, Möller P, Brüderlein S, Guppy N, Amary F, Tirabosco R, Strauss SJ, Pillay N, Flanagan AM. (2016). EGFR inhibitors Identified as a Potential Treatment for Chordoma in a Focused Compound Screen. J Pathol. Apr 22.
  30. Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, Wedge DC, Cooke SL, Gundem G, Davies H, Nik-Zainal S, Martin S, McLaren S, Goodie V, Robinson B, Butler A, Teague JW, Halai D, Khatri B, Myklebost O, Baumhoer D, Jundt G, Hamoudi R, Tirabosco R, M Amary F, Futreal PA, Stratton MR, Campbell PJ, Flanagan AM (2013) Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nature Genet. 45:1479-1482
  31. Patrick S Tarpey PS, Behjati S, Susanna Cooke S, Van Loo P, Wedge DC, Pillay N, John Marshall J, O’Meara S, Davies H, Nik-Zainal S, Beare D, Butler A, Gamble J, Hardy C, Hinton C, Jia MM, Jayakumar A, Jones, D, Latimer C, Maddison M, Martin S, McLaren S, Menzies A, Mudie L, Raine K, Teague JW, Tubio J, Halai D, Tirabosco R, Amary F, Campbell PJ, Stratton MR, Flanagan AM, Futreal AM (2013) Frequent mutation of the major cartilage collagen gene, COL2A1, in chondrosarcoma. Nature Genet. 45:923-926
  32. Guilhamon P, Eskandarpour M , Halai D, Wilson GA, Feber A, Teschendorff AE, Gomez V, Hergovich A, Tirabosco R, Amary MF, Baumhoer D, Jundt G, Ross MT, Flanagan AM, Beck S (2013) Meta-analysis of IDH-mutant cancers identifies EBF1 as a novel interaction partner for TET2. Nature Comm. 4:2166-2175
  33. Savage SA, Mirabello l, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, Flanagan AM, Tirabosco R, Andrulis IL, Wunder JS, Gokgoz N, Patiño-Garcia A, Sierrasesúmaga L, Lecanda F, Kurucu N, Ilhan IE, Sari N, Serra M, Hattinger C, Picci P, Spector LG, barkauskas da, Marina n, de toledo sr, petrilli as, Amary MF, Halai D, Thomas DM, Douglass C, Meltzer PS, Jacobs K, Chung CC, Berndt SI, Purdue MP, Caporaso NE, Tucker M, Rothman N, Landi MT, Silverman DT, Kraft P, Hunter dj, malats n, kogevinas m, wacholder S, Troisi R, Helman L, Fraumeni JF Jr, Yeager M, Hoover RN, Chanock SJ (2013) Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nature Genet. 45:799-803
  34. Amary MF, Damato S, Halai D, Eskandarpour M, Berisha F, Bonar F, McCarthy S, Fantin VR, Straley KS, Lobo S, Aston W, Green CL, Gale RE, Tirabosco R, Futreal A, Campbell P, Presneau N, Flanagan AM (2011) Ollier disease and Maffuci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nature Genet. 43:1262-1265
  35. Pillay N, Plagnol V, Tarpey PS, Lobo S, Presneau N, Szuhai K, Halai D, Berisha F, Cannon SR, Mead S, Kasperavicute D, Palmen J, Talmud P, Kindblom LG, Amary MF, Tirabosco R, Flanagan AM. (2012) A common single nucleotide variant in T is strongly associated with chordoma. Nature Genet. 14:1185-1197
  36. Nelson AC, Pillay N, Henderson S, Presneau N, Tirabosco R, Halai D, Berisha F, Flicek P, Stemple DL, Stern C, Wardle FC, Flanagan AM. (2012) An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma. J Pathol. 228:274-285
  37. Presneau N, Eskandarpour M, Shemais T, Henderson S, Halai D, Tirabosco R, Flanagan AM. Micro-RNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression. Brit. J. Cancer 2012 Nov 22. doi: 10.1038/bjc.2012.518
  38. Kashima TG, Halai D, Ye H, Hing SN, Delaney D, Robin Pollock R, O’Donnell P, Tirabosco R, Flanagan AM (2012) Sensitivity of MDM2 amplification and unexpected multiple faint alphoid 12 (alpha 12 satellite sequences) signals in atypical lipomatous tumor and well differentiated liposarcoma. Mod. Pathol. 5:1384-96
  39. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, Pollock R, O’Donnell P, Grigoriadis A, Diss T, Eskandarpour M, Presneau N, Hogendoorn PC, Futreal A, Tirabosco R, Flanagan AM (2011) IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J. Pathol. 224:334-343. 
    ​Winner of the Jeremy Jass prize for Research Excellence in Pathology - 2011.
  40. Amary MF, Damato S, Halai D, Eskandarpour M, Berisha F, Bonar F, McCarthy S, Fantin VR, Straley KS, Lobo S, Aston W, Green CL, Gale RE, Tirabosco R, Futreal A, Campbell P, Presneau N, Flanagan AM (2011) Ollier disease and Maffuci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nature Genet. 43:1262-1265
  41. Damato S, Alorjani M, Bonar F, McCarthy SW, Cannon SR, O’Donnell P, Tirabosco R, Amary MF, Flanagan AM (2012) IDH1 mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas. Histopathology 60:363-365
  42. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, Pleasance ED, Lau KW, Beare D, Stebbings LA, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal S, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Quail MA, Burton J, Swerdlow H, Carter NP, Morsberger LA, Iacobuzio-Donahue C, Follows GA, Green AR, Flanagan AM, Stratton MR, Futreal PA, Campbell PJ (2011) Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144:27-40
  43. Presneau N, Shalaby A, Idowu B, Gikas P, Cannon SR, Gout I, Diss T, Tirbabosco R, Flanagan AM (2009) Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway. Br. J. Cancer 100:1406-1414
  44. Shalaby AA, Presneau N, Idowu BD, Thompson L, Briggs TR, Tirabosco R, Diss TC, Flanagan AM (2009) Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas. Mod. Pathol. 22:996-1005
  45. Shalaby A, Presneau N, Ye H, Halai D, Berisha F, Idowu B, Leithner A, Liegl B, Briggs TWR, Bacsi K, Kindblom LG, Athanasou N, Amary MF, Hogendoorn PCW, Tirabosco R, Flanagan AM (2010) The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target. J. Pathol. 223:336-346
  46. Presneau N, Shalaby A, Ye H, Pillay N, Halai D, Idowu B, Tirabosco R, Whitwell D, Jacques T, Kindblom LG, Bruderlein S, Moller P, Leithner A, Liegl B, Amary MF, Athanasou NN, Hogendoorn PCW, Mertens F, Szuhai K, Flanagan AM (2010) Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study. J. Pathol. 223:327-335
  47. Vujovic S, Henderson S, Presneau N, Odell E, Jacques T, Tirabosco R, Boshoff C and Flanagan AM (2006) Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J. Pathol. 209:157-165
  48. Tirabosco R, Mangham DC, Rosenberg AE, Vujovic S, Bousdras K, Pizzolitto S, De Maglio G, den Bakker MA, Di Francesco L, Kalil RK, Athanasou NA, O’Donnell P, McCarthy EF and Flanagan AM (2008) Brachyury expression in extra-axial skeletal and soft tissue chordomas: A marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue. Am. J. Surg. Pathol. 32:572-580
Previous responsibilities

Prof Falnagan is a guest Faculty Member at the The 5th Annual Sacro Pelvic Tumor Study Group Conference held by the Massachusetts General Hospital (Boston, MA), the Mayo Clinic (Rochester, MN) and the Memorial Sloan-Kettering Cancer Center (New York, NY ). The conference was was founded in 2008 as a collaboration with Massachusetts General Hospital (Boston, MA ), the Mayo Clinic (Rochester, MN) and the Memorial Sloan-Kettering Cancer Center (New York, NY).

2013 - Elected a Meeting Secretary of the Pathological Society of Great Britain and Ireland (officer of the society)

2013 - Appointed Head of Pathology (research)  at UCL in February

2013 - Corporate License Holder of the Human Tissue Authourity license, UCL - which now includes biobank at RNOH

2012 - Biomedical Research Centre (UCLH/UCL), Cancer Programme Deputy Director

2013 - Sarcoma UK Research Advisory Committee

2012 - Trustee of the Jean Shanks Foundation

Designated Individual of Human Tissue Authourity licence (research), UCL (2009-2012)
Medical Director, RNOH (2009 – 2012)
Cancer Research UK Stratified Medicine, scientific advisory board member (2010-2011)
Chair of the Medical Staff Committee RNOH (2007-2009)
Co-Chair of the Medical Staff Committee RNOH (2005-2007)
Pathological Society of Great Britain and Ireland (2007-2009)

How helpful did you find this page?
Not helpful
Very helpful *
Required fields *

Health Professionals